About Lisata Therapeutics, Inc. - Common Stock (LSTA)
Lisata Therapeutics, Inc. is a biotechnology company focused on the development of innovative therapies to address unmet medical needs in various disease areas. The company specializes in creating novel treatments that target specific health conditions, with an emphasis on delivering effective solutions to improve patient outcomes. Through rigorous research and development, Lisata aims to advance its pipeline of therapeutic candidates and contribute to the future of healthcare by harnessing the potential of scientific advancements in biotechnology. Read More
Gainers AVITA Medical (NASDAQ:RCEL) stock moved upwards by 11.1% to $4.9 during Thursday's after-market session. The market value of their outstanding shares is at $143.1 million. Lisata Therapeutics (NASDAQ:LSTA)
Lisata stockholders to receive $4.00 per share in cash at closing, plus one non-tradeable contingent value right, which represents the contractual right to receive two contingent cash payments of up to an aggregate of $3.00 per share, subject to achievement of specified milestones
BALA CYNWYD, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
BALA CYNWYD, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Each Lisata stockholder to receive $5.00 per share in cash payable at closing plus one contingent value right for a potential additional cash payment of $1.00 per share
BALA CYNWYD, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Lisata Therapeutics, Inc. (NASDAQ: LSTA) to Kuva Labs, Inc. for $4.00 per share in cash plus two non-tradeable contingent value rights payable under certain conditions is fair to Lisata shareholders.
Lisata said that it has entered into a binding term sheet under which the two companies agreed to negotiate in good faith and enter into a customary purchase agreement.
BALA CYNWYD, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Stockholders to also receive two contingent value rights valued at $1 per share, each entitled to be received upon the achievement of certain milestones
